

-- 12. A method of extending the serum half life of a protein having a first region capable of binding to an FcRb receptor, the method comprising:

joining to said protein at least a second region capable of binding to an FcRb receptor. --

-- 13. The method of claim 12 wherein said receptor is selected from the group consisting of FcRn, FcRb and FcRp. --

-- 14. The method of claim 12 wherein said receptor is FcRn.--

-- 15. The method of claim 12 wherein said receptor is FcRb.--

-- 16. The method of claim 12 wherein said receptor is FcRp.--

-- 17. The method of claim 12 wherein said first region is an Fc region. --

-- 18. The method of claim 17 wherein said first region is an IgG Fc region. --

-- 19. The method of claim 12 wherein said protein is an antibody. --

-- 20. The method of claim 19 wherein said antibody is specific for IL-8. --

-- 21. The method of claim 19 wherein said antibody comprises an IgG heavy chain. --

-- 22. The method of claim 19 wherein said antibody comprises a dimer. --

-- 23. The method of claim 19 wherein said antibody is a human antibody. --

-- 24. The method of claim 12 wherein said joining is by recombinant fusion. --

-- 25. The method of claim 12 where said at least second region is linearly joined to the C-terminus of said first region.--

-- 26. The method of claim 12 wherein said first and second regions are identical. --

-- 27. A modified protein with an extended serum half life, said modified protein comprising:

a first region capable of binding to an FcRb receptor; and

at least a second region capable of binding to an FcRb receptor. --

-- 28. The modified protein of claim 27 wherein said receptor is selected from the group consisting of FcRn, FcRb and FcRp. --

-- 29. The modified protein of claim 27 wherein said receptor is FcRn. --

-- 30. The modified protein of claim 27 wherein said receptor is FcRb. --

-- 31. The modified protein of claim 27 wherein said receptor is FcRp. --

-- 32. The modified protein of claim 27 wherein said first region is an Fc region. --

-- 33. The modified protein of claim 27 wherein said first region is an IgG Fc region. --

-- 34. The modified protein of claim 29 wherein said protein is an antibody. --

-- 35. The antibody of claim 34 wherein said antibody is specific for IL-8. --

-- 36. The antibody of claim 34 wherein said antibody comprises an IgG heavy chain. --

-- 37. The antibody of claim 34 wherein said antibody comprises a dimer. --

-- 38. The antibody of claim 34 wherein said antibody is a human antibody. --

-- 39. The modified protein of claim 27 wherein said joining is by recombinant fusion. --

a' -- 40. The modified protein of claim 27 where said at least second region is joined to the C-terminus of said first region. --

-- 41. The modified protein of claim 27 wherein said first and second regions are identical. --

-- 42. A method of increasing the avidity or affinity of a protein to a receptor, said protein having a first region capable of binding to said receptor, said method comprising joining to said protein at least a second region capable of binding to said receptor. --